about
Erytrocyte membrane anionic charge in type 2 diabetic patients with retinopathyCirculating IGF-I and its protective role in the pathogenesis of diabetic angiopathy.Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjectsImpaired microvascular properties in uncomplicated type 1 diabetes identified by Doppler ultrasound of the ocular circulation.The Vanderbilt Classification System in the evaluation of diabetic retinopathy patients treated with Alredase.Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.High-intensity endurance training results in faster vessel-specific rate of vasorelaxation in type 1 diabetic ratsOcular perfusion abnormalities in diabetes.Hyperactivity of ON-type retinal ganglion cells in streptozotocin-induced diabetic mice.Serum insulin-like growth factor-I in diabetic retinopathy.Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitusNeovascular growth factors.Production of IGF-I and IGF binding proteins by retinal cells in vitro.Factors influencing the natural history of diabetic retinopathy.Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.Hemorheological disorders in diabetes mellitusMultimodal functional and anatomic imaging identifies preclinical microvascular abnormalities in type 1 diabetes mellitus.Upregulation of glutamate-aspartate transporter by glial cell line-derived neurotrophic factor ameliorates cell apoptosis in neural retina in streptozotocin-induced diabetic rats.Microvascular haemodynamics in diabetes.Differences in the synthesis of secreted proteins in human retinal endothelial cells of diabetic and nondiabetic origin.Vessel-specific rate of vasorelaxation is slower in diabetic rats.Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations.
P2860
Q24792124-07FBB3F9-D33B-4A46-BB3C-8BF302594F77Q33826397-A516E8F7-9192-42BB-BD65-AC85CD0D4B88Q33909613-DAB8A32E-FFB9-4CD0-8DC9-8D8E3FA7D64DQ33926623-F82A082D-1FA8-4845-8FFB-5976B7C768D3Q34211427-3F951293-423B-437E-A8FF-8CADD1907AF3Q34265356-BB957169-85F6-4386-A5E0-9CEA50A3E216Q34635427-3A0CBA89-12E5-41D1-95F7-8EDAFFC59A8BQ34975866-D8EC0A98-144A-42B9-8A69-C88D0D1B8665Q34999756-2A99979A-9EA9-403E-8CAF-614FD86AE686Q35209182-313205D6-771A-4508-B33A-C365F0A21D87Q35610369-4A666006-702E-4F96-8EFA-F25D90F6595DQ36664516-BB5B1945-3476-42CC-8042-6F6F3D200076Q36676107-56BC8B0C-4F60-4A53-8203-F2A5B917D10CQ36686896-103C0F5C-8922-4A8D-9865-BD052926F2A3Q37350875-760A1699-AD43-4C7B-B4F7-8CF9A3CED124Q37626485-B5F32873-303D-4725-B75A-C3B600489702Q39118968-4F4CDFA8-F3AF-43FF-9600-F1C7A3946CCCQ39123343-5D8209A6-F7A1-4A8E-802F-235D13A0F434Q40442549-DFCB53C9-0045-4AB2-92A0-B6D9A7FA8799Q42495523-AA9D688E-4A7E-402D-B68F-44057478D40FQ44222368-4714490D-D1E2-4442-86B6-2EC2CCB02987Q48580864-6BDA9505-CB37-488D-B51F-4FB62F749BBD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Diabetic retinopathy. A synthesis of perspectives.
@en
Diabetic retinopathy. A synthesis of perspectives.
@nl
type
label
Diabetic retinopathy. A synthesis of perspectives.
@en
Diabetic retinopathy. A synthesis of perspectives.
@nl
prefLabel
Diabetic retinopathy. A synthesis of perspectives.
@en
Diabetic retinopathy. A synthesis of perspectives.
@nl
P1476
Diabetic retinopathy. A synthesis of perspectives.
@en
P2093
Merimee TJ
P304
P356
10.1056/NEJM199004053221406
P407
P577
1990-04-01T00:00:00Z